An Immune Dysregulation in MPN

Current Hematologic Malignancy Reports
9, 331-339
DOI: 10.1007/s11899-014-0227-0

#	Article	IF	Citations
1	The impact of ruxolitinib treatment on inflammationâ€mediated comorbidities in myelofibrosis and related neoplasms. Clinical Case Reports (discontinued), 2015, 3, 499-503.	0.5	14
2	MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-16.	3.0	155
3	The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	63
4	Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm. Mediators of Inflammation, 2015, 2015, 1-6.	3.0	36
5	Immunological Consequences of JAK Inhibition: Friend or Foe?. Current Hematologic Malignancy Reports, 2015, 10, 370-379.	2.3	84
6	Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?. Leukemia and Lymphoma, 2016, 57, 1793-1799.	1.3	19
7	Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood, 2016, 128, 1660-1662.	1.4	13
8	Interferon-alfa â€“ 30 years of clinical experience. Leukemia Research, 2016, 44, S3-S4.	0.8	0
9	Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia, 2016, 30, 776-781.	7.2	109
10	Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leukemia and Lymphoma, 2016, 57, 1054-1059.	1.3	18
11	Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leukemia and Lymphoma, 2016, 57, 125-128.	1.3	16
12	Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology, 2017, 10, 393-404.	2.2	25
13	Anaemia and â€˜triple-negativeâ€™ bone marrow fibrosis: a diagnostic conundrum. Pathology, 2017, 49, 426-427.	0.6	0
14	The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leukemia and Lymphoma, 2017, 58, 1914-1921.	1.3	17
15	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews, 2017, 31, 17-29.	5.7	98
16	GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Review of Hematology, 2018, 11, 169-184.	2.2	28
17	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. OncoImmunology, 2018, 7, e1433521.	4.6	30
18	Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. Hematology, Transfusion and Cell Therapy, 2018, 40, 120-131.	0.2	30

#	Article	IF	Citations
19	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	4.6	19
20	Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance. Oncology Reviews, 2018, 12, 373.	1.8	4
21	Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology, 2018, 7, e1468957.	4.6	15
22	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	2.2	6
23	A journey through infectious risk associated with ruxolitinib. British Journal of Haematology, 2019, 187, 286-295.	2.5	28
24	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. International Journal of Molecular Sciences, 2019, 20, 5459.	4.1	17
25	The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2019, 14, 310-327.	2.3	21
26	Myeloidâ€Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. HemaSphere, 2019, 3, e168.	2.7	41
27	Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology, 2019, 41, 5-19.	6.1	71
28	Myeloproliferative and lymphoproliferative disorders: State of the art. Hematological Oncology, 2020, 38, 121-128.	1.7	16
29	Novel targets to cure primary myelofibrosis from studies on <i>Gata1</i>^{low} mice. IUBMB Life, 2020, 72, 131-141.	3.4	5
30	Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?. HemaSphere, 2020, 4, e407.	2.7	8
31	The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis. OncoImmunology, 2020, 9, 1782575.	4.6	20
32	Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica, 2020, 106, haematol.2020.249441.	3.5	2
33	Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells, 2020, 9, 2136.	4.1	26
34	Role of inflammation in the biology of myeloproliferative neoplasms. Blood Reviews, 2020, 42, 100711.	5.7	49
35	Immunotherapy in Myeloproliferative Diseases. Cells, 2020, 9, 1559.	4.1	17
36	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers, 2020, 12, 1763.	3.7	17

#	Article	IF	Citations
37	Impaired virusâ€specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. Hematological Oncology, 2020, 38, 554-559.	1.7	4
38	Alterations of T-cell-mediated immunity in acute myeloid leukemia. Oncogene, 2020, 39, 3611-3619.	5.9	52
39	Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients. International Journal of Molecular Sciences, 2020, 21, 2926.	4.1	8
40	Risk of infections in patients with myeloproliferative neoplasmsâ€"a population-based cohort study of 8363 patients. Leukemia, 2021, 35, 476-484.	7.2	32
41	Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. British Journal of Haematology, 2021, 193, 150-154.	2.5	10
42	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 637420.	2.8	29
43	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. International Journal of Molecular Sciences, 2021, 22, 1906.	4.1	19
44	Autoimmune Complications in Hematologic Neoplasms. Cancers, 2021, 13, 1532.	3.7	36
45	Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers, 2021, 13, 2552.	3.7	9
46	Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. Journal of Clinical Medicine, 2021, 10, 2788.	2.4	15
47	NK Cells in Myeloproliferative Neoplasms (MPN). Cancers, 2021, 13, 4400.	3.7	0
49	The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: â€œCraftingâ€a Microenvironment That Matters. Cells, 2021, 10, 2316.	4.1	8
50	Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers, 2021, 13, 4750.	3.7	8
51	Immune Complex Associated Glomerulonephritis in a Patient with Prefibrotic Primary Myelofibrosis: A Case Report. Indian Journal of Nephrology, 2021, 31, 50.	0.5	0
52	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis. PLoS ONE, 2016, 11, e0161570.	2.5	6
53	Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLoS ONE, 2017, 12, e0183620.	2.5	51
54	Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. Frontiers in Immunology, 2021, 12, 750346.	4.8	6
55	<scp>PDâ€L1</scp> overexpression correlates with <scp><i>JAK2</i>â€V617F</scp> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, 390-400.	4.1	8

#	Article	IF	Citations
56	Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia, 2022, 36, 1176-1179.	7.2	3
57	CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms. Genes, 2022, 13, 492.	2.4	3
58	Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity. Leukemia Research, 2022, 116, 106819.	0.8	5
59	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology, 2022, 13, .	4.8	0
60	ĐœÑ–Ñ”Đ»Đ¾Đ¿Ñ€Đ¾Đ»Ñ–Ñ„ĐµÑ€Đ°Ñ‚Đ¸Đ²Đ½Ñ– Ñ‚Đ° Đ»Ñ–Đ¼Ñ„Đ¾Đ¿Ñ€Đ¾Đ»Ñ–Ñ„ĐµÑ€Đ°Ñ‚Đ¸Đ²Đ½Ñ–Đ·Đ°Ñ…Đ²Đ¾Ñ€	0.1	0
61	Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLoS ONE, 2022, 17, e0270669.	2.5	6
62	Diffuse Large B-Cell Epstein-Barr Virusâ€"Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics. American Journal of Neuroradiology, 0, , .	2.4	5
63	Ageâ€related macular degeneration and myeloproliferative neoplasms â€" A common pathway. Acta Ophthalmologica, 2022, 100, 3-35.	1.1	3
64	Exploring the Implementation of Compact Chromatographic Instrumentation in Common Analytical Workflows. LC-GC North America, 2022, , 41-43.	0.5	0
65	Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022. American Journal of Neuroradiology, 2023, 44, 358-366.	2.4	6
66	An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. Frontiers in Immunology, 0, 14, .	4.8	3
68	Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomarker Research, 2023, 11, .	6.8	8
69	Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis. Advances in Experimental Medicine and Biology, 2023, , 273-290.	1.6	0
70	Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. International Journal of Molecular Sciences, 2023, 24, 12502.	4.1	1
71	Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms. Cancers, 2023, 15, 4323.	3.7	2
72	Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow. Frontiers in Immunology, 0, 14, .	4.8	0
73	Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors. European Journal of Internal Medicine, 2023, , .	2.2	0
74	Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities. Heliyon, 2024, 10, e25081.	3.2	0

#	Article	IF	Citations
75	Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation. European Journal of Haematology, 2024, 112, 938-943.	2.2	0